Alithea Bio to Present HLA-Compass AI Breakthroughs at CIMT 2026 in Mainz

Next week, the global cancer immunotherapy community will gather at the Rheingoldhalle Congress Center for the 23rd CIMT Annual Meeting. Alithea Bio is proud to participate in this high-level scientific exchange, showcasing our latest advancements in off-target toxicity prediction and target validation.

Visit Our Poster: HLA-Compass AI in Action

We invite all attendees to join Gloria Kraus during Poster Session II on Tuesday, May 12th, for an in-depth look at our recent research:

• Poster Title: Enhanced prediction of Peptide-HLA Binding and Off-Target Toxicity Using HLA-Compass AI
• Poster Number: 161
• Key Focus: How our AI-guided SaaS platform—the world’s largest quantitative database of HLA peptide presentation—is revolutionizing the way researchers identify and validate safe, effective immunotherapy targets.

Why Alithea Bio at CIMT?
As Europe’s largest non-profit meeting dedicated to cancer immunotherapy, CIMT is the ideal venue to discuss the translation of research into medical innovations. At Alithea Bio, we specialize in:

• Absolute quantification of HLA peptides.
• Off-target toxicity screening using real-world biological data from healthy and tumor tissues.

• Neoantigen detection via our NeoZoom pipeline.

Let’s Connect in Mainz
Since the conference does not use a digital partnering portal, we encourage you to connect with Gloria Kraus directly via LinkedIn or meet her at the poster hall to discuss potential collaborations.
We look forward to seeing you in Mainz and working together to advance the future of individualized immune intervention!